Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

Let's examine two reasons why the stock is worth buying, and one reason why it makes sense to be just a little bit cautious ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...